Neuphoria Therapeutics Inc. — Form 8-K
Filed October 23, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
Neuphoria Therapeutics amended its Rights Agreement with Computershare Trust Company, N.A., extending the Final Expiration Date from October 27, 2026 to October 27, 2027. The amendment was authorized by the Board of Directors and executed by Interim CEO Spyridon Papapetropoulos on October 23, 2026. No financial terms, triggering events, or material conditions were disclosed.
Why this rating
Routine administrative extension of shareholder rights plan; no operational, financial, or strategic change disclosed relative to $7M market cap.
See more from October 23, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.